The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites
Open accessAbstract
Bromodomains are readers of the epigenetic code that specifically bind acetyl-lysine containing recognition sites on proteins. Recently the BET family of bromodomains has been demonstrated to be druggable through the discovery of potent inhibitors, sparking an interest in protein-protein interaction inhibitors that directly target gene transcription. Here, we assess the druggability of diverse members of the bromodomain family using SiteMap and show that there are significant differences in predicted druggability. Furthermore, we trace these differences in druggability back to unique amino acid signatures in the bromodomain acetyl-lysine binding sites. These signatures were then used to generate a new classification of the bromodomain family, visualized as a classification tree. This represents the first analysis of this type for the bromodomain family and can prove useful in the discovery of inhibitors, particularly for anticipating screening hit rates, identifying inhibitors that can be explored for lead hopping approaches, and selecting proteins for selectivity screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
Chen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,742
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Self-citationAn inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Ligand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Identifying and Characterizing Binding Sites and Assessing Druggability
Halgren, T. A. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800324m · Cited by 1,759
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.-P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.013 · Cited by 1,694
Self-citationSuppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
Bromodomain: an acetyl‐lysine binding domain
Zeng, L., & Zhou, M.-M. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03309-9 · Cited by 746
Structure-based maximal affinity model predicts small-molecule druggability
Cheng, A. C., Coleman, R. G., Smyth, K. T., Cao, Q., Soulard, P., Caffrey, D. R., Salzberg, A. C., & Huang, E. S. (2007) · Nature Biotechnology · doi:10.1038/nbt1273 · Cited by 695
Combining Global and Local Measures for Structure-Based Druggability Predictions
Volkamer, A., Kuhn, D., Grombacher, T., Rippmann, F., & Rarey, M. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200454v · Cited by 496
Bromodomains as therapeutic targets
Muller, S., Filippakopoulos, P., & Knapp, S. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001992 · Cited by 442
Self-citationStructure and acetyl-lysine recognition of the bromodomain
Mujtaba, S., Zeng, L., & Zhou, M.-M. (2007) · Oncogene · doi:10.1038/sj.onc.1210618 · Cited by 421
Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains
Chung, C.-W., Coste, H., White, J. H., Mirguet, O., Wilde, J., Gosmini, R. L., Delves, C., Magny, S. M., Woodward, R., Hughes, S. A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200108t · Cited by 334
Schmidtke, P., & Barril, X. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100574m · Cited by 331
Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL
Bruncko, M., Oost, T. K., Belli, B. A., Ding, H., Joseph, M. K., Kunzer, A., Martineau, D., McClellan, W. J., Mitten, M., Ng, S.-C., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061152t · Cited by 304
Analyzing the Topology of Active Sites: On the Prediction of Pockets and Subpockets
Volkamer, A., Griewel, A., Grombacher, T., & Rarey, M. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100241y · Cited by 300
fpocket: online tools for protein ensemble pocket detection and tracking
Schmidtke, P., Le Guilloux, V., Maupetit, J., & Tuffery, P. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq383 · Cited by 290
Predicting protein druggability
Hajduk, P. J., Huth, J. R., & Tse, C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03624-x · Cited by 289
Nayal, M., & Honig, B. (2006) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20897 · Cited by 284
3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands
Hewings, D. S., Wang, M., Philpott, M., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Vuppusetty, C., Marsden, B., Knapp, S., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200640v · Cited by 216
Self-citationFauman, E. B., Rai, B. K., & Huang, E. S. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.020 · Cited by 181
Selective Small Molecules Blocking HIV-1 Tat and Coactivator PCAF Association
Zeng, L., Li, J., Muller, M., Yan, S., Mujtaba, S., Pan, C., Wang, Z., & Zhou, M.-M. (2005) · Journal of the American Chemical Society · doi:10.1021/ja044885g · Cited by 160
Sachchidanand, Resnick‐Silverman, L., Yan, S. X., Mutjaba, S., Liu, W., Zeng, L., Manfredi, J. J., & Zhou, M. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.10.014 · Cited by 145
Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery
Philpott, M., Yang, J., Tumber, T., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Keates, T., Felletár, I., Ciulli, A., et al. (2011) · Molecular BioSystems · doi:10.1039/c1mb05099k · Cited by 141
Self-citationA Small Molecule Binding to the Coactivator CREB-Binding Protein Blocks Apoptosis in Cardiomyocytes
Borah, J. C., Mujtaba, S., Karakikes, I., Zeng, L., Müller, M., Patel, J. A., Moshkina, N., Morohashi, K., Zhang, W., Gerona‐Navarro, G., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.12.021 · Cited by 136
Sheridan, R. P., Maiorov, V. N., Holloway, M. K., Cornell, W. D., & Gao, Y. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100312t · Cited by 126
Krasowski, A., Muthas, D., Sarkar, A., Schmitt, S., & Brenk, R. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200266d · Cited by 103
Structural Chemistry of the Histone Methyltransferases Cofactor Binding Site
Campágna‐Slater, V., Mok, M. W., Nguyen, K. T., Fehér, M., Najmanovich, R., & Schapira, M. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci100479z · Cited by 82
Druggability of methyl-lysine binding sites
Santiago, C., Nguyen, K., & Schapira, M. (2011) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9505-2 · Cited by 80
Cited by
Targeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,243
Self-citationSmall-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Picaud, S., Wells, C., Felletar, I., Brotherton, D., Martin, S., Savitsky, P., Diez-Dacal, B., Philpott, M., Bountra, C., Lingard, H., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310658110 · Cited by 468
Self-citationBromodomain inhibitors and cancer therapy: From structures to applications
Pérez-Salvia, M., & Esteller, M. (2017) · Epigenetics · doi:10.1080/15592294.2016.1265710 · Cited by 292
Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
Hay, D. A., Fedorov, O., Martin, S., Singleton, D. C., Tallant, C., Wells, C., Picaud, S., Philpott, M., Monteiro, O. P., Rogers, C. M., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja412434f · Cited by 277
Self-citation
Metadata
- Authors
- Vidler, L. R., Brown, N., Knapp, S., & Hoelder, S.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-07-12
- Volume
- 55
- Issue
- 17
- Pages
- 7346-7359
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2028561673
- Cited by
- 278
- References
- 35
- FWCI
- 8.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.